Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

@article{Rosenstock2004RepaglinideVN,
  title={Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.},
  author={Julio Rosenstock and David R. Hassman and Robert Madder and Shari A. Brazinsky and James Farrell and Naum M. Khutoryansky and Paula M. Hale},
  journal={Diabetes care},
  year={2004},
  volume={27 6},
  pages={
          1265-70
        }
}
OBJECTIVE A randomized, parallel-group, open-label, multicenter 16-week clinical trial compared efficacy and safety of repaglinide monotherapy and nateglinide monotherapy in type 2 diabetic patients previously treated with diet and exercise. RESEARCH DESIGN AND METHODS Enrolled patients (n = 150) had received treatment with diet and exercise in the previous 3 months with HbA(1c) >7 and < or =12%. Patients were randomized to receive monotherapy with repaglinide (n = 76) (0.5 mg/meal, maximum… 

Figures and Tables from this paper

Nateglinide versus repaglinide for type 2 diabetes mellitus in China
TLDR
The adverse reaction rate in the nateglinide group is higher than that in the latter using repaglinide but no statistical significance difference as revealed in the four clinical trials detailed below.
Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
TLDR
The combination therapy produced significant reductions in HbA1c, AUC of glucose and fasting glucose compared with switching to repaglinide without weight gain or severe hypoglycemia, and the improved glycemic control with this combination therapy may be at least in part due to augmentation of repaglinside-induced insulin secretion by sitagliptin.
Multicentre, Double-blind, Randomized Study of Mitiglinide Compared with Nateglinide in Type 2 Diabetes Mellitus Patients in China
  • X. Gao
  • Medicine
    The Journal of international medical research
  • 2009
TLDR
Investigation of the non-inferiority of mitiglinide 10–20 mg versus nateglinide 120 mg, given orally three times daily for 20 weeks, in 291 Chinese type 2 diabetes mellitus patients in whom adequate blood glucose control had not been achieved by diet and exercise found it provided similarBlood glucose control to nategliad 120 mg three timesdaily in type 2 DM patients, including the elderly and patients with mild diabetes mell Titus.
Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes
TLDR
The combination of nateglinide and metformin provides a sustained degree of glycemic control not achievable with either agent given as monotherapy.
POTENTIAL ADVANTAGE OF REPAGLINIDE MONOTHERAPY IN GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES AND SEVERE RENAL IMPAIRMENT.
TLDR
The efficacy of repaglinide was demonstrated in patients with T2D and severe RI and in case that DPP-4 inhibitors are not enough to achieve targeted range of glycemic control, repaglinside is another good candidate.
Comparison of the efficacy of repaglinide versus the combination of mitiglinide and voglibose on glycemic variability in Japanese patients with type 2 diabetes.
TLDR
Treatment with the combination of mitiglinide and voglibose might be more effective than repaglinide for the improvement of glycemic variability in Japanese patients with type 2 diabetes.
Head to head comparison of Nateglinide versus Glimepiride monotherapy in Type-2 diabetes
TLDR
It was obvious that both glimepiride and nateglinide are effective, but the decrease in PPBS and HbA1c% was more with nategliide.
A randomized controlled study for evaluation of psyllium effects on kinetics of carbohydrate absorption
TLDR
This pilot study revealed that psyllium may effectively reduce postprandial plasma glucose possibly by retarding GI carbohydrate absorption in diet-treated type 2 diabetic patients.
Comparative study of safety and efficacy profile of repaglinide and voglibose on targeting post prandial hyperglycemia in patients with newly diagnosed type II diabetes mellitus
TLDR
Though repaglinide and voglibose were equally effective in improving glycemic indices yet repagliide showed better results in improving HbA1c, FBG, PBS as compared with vog Libose, Repaglinides had minimal side effects as compared to vog libose.
Repaglinide as a safe alternative against hypoglycemia in fasting elderly diabetic patients: A single blinded, placebo-controlled, six period, cross-over study
TLDR
The present study suggests that in case of elderly diabetic patients, who may miss meals, repaglinide is a safe alternative to other antidiabetics, as for nateglinide, further studies are required.
...
...

References

SHOWING 1-10 OF 21 REFERENCES
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
TLDR
The addition of repaglinide to metformin therapy resulted in reductions of HbA(1c) and FPG values that were significantly greater than the reductions observed for addition of nateglinide.
Repaglinide versus glyburide: a one-year comparison trial.
Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.
TLDR
The combination of nateglinide and of a thiazolidinedione shows an additive effect that is highly effective in reducing HbA(1c) levels to the target of <7% in 66% of patients, from a baseline HBA( 1c) that is just above 8%.
Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
TLDR
Mealtime dosing with repaglinide is effective in improving overall glycemic control in type 2 diabetic patients for which control is suboptimal using diet alone.
Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
TLDR
It is demonstrated that nateglinide improves mealtime and mean glycemic control in a dose-dependent manner by restoring early insulin secretion phase and is suitable for the treatment of patients with type 2 diabetes.
Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
TLDR
Acute premeal administration of nateglinide or glipizide has equal efficacy in controlling postbreakfast hyperglycemia in type 2 diabetes when each drug is administered at the optimum time before the meal.
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
TLDR
With few exceptions, the available oral antidiabetic agents are equally effective at lowering glucose concentrations and their mechanisms of action are different, however, and as a result they appear to have distinct metabolic effects.
...
...